Literature DB >> 9188816

Human pre-alpha-inhibitor: isolation from a by-product of industrial scale plasma fractionation and structural analysis of its H3 heavy chain.

C Mizon1, A Héron, C Capon, P Sautiere, C Michalski, R Sesboüé, J Mizon.   

Abstract

Pre-alpha-inhibitor (P alpha I) is a serine proteinase inhibitor from human plasma. It comprises bikunin (BK) responsible for antiprotease activity, covalently linked to a heavy chain H3. Here we describe its isolation from a side fraction of an industrial preparation of plasma clotting factors. By using a highly specific polyclonal antiserum prepared from rabbit immunized with a H3P polypeptide obtained in a bacterial expression system, we were able to identify the fractions containing P alpha I. Then, taking advantage of the differential affinity of the members of the inter-alpha-inhibitor family (I alpha I) for heparin-Sepharose and blue-Sepharose, we isolated P alpha I. Its specific antitryptic activity was 580 IU/g, higher than that of I alpha I: 420 IU/g. Its M(r), determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis, with or without prior reduction, was 130,000. Its peptide chains were identified by N-terminal sequencing. The H3 heavy chain was isolated from P alpha I by alkaline dissociation and anion-exchange chromatography. Its electrophoretic mobility was compared to that of the HI and H2 heavy chains of I alpha I. In reducing conditions, it was quite similar to that of H2 (M(r) 85,000) but clearly different from that of H1 (M[r] 78,000). Thus, the so-determined apparent M(r) of H3 was overestimated since its molecular mass determined by MALDI-TOF was 74,100. This result agrees with the proposed structure for H3. Indeed, by carbohydrate analysis and PNGase F digestion, we demonstrate that the two potential N-glycosylation sites present in the core-protein (theoretical mass: 69,454) are really occupied by two N-glycans, probably of biantennary type.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9188816     DOI: 10.1016/s0378-4347(97)00012-1

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  4 in total

Review 1.  The role of proteomics in plasma fractionation and quality control of plasma-derived therapeutic proteins.

Authors:  Dajana Gaso-Sokac; Djuro Josic
Journal:  Blood Transfus       Date:  2010-06       Impact factor: 3.443

2.  TSG-6 potentiates the antitissue kallikrein activity of inter-alpha-inhibitor through bikunin release.

Authors:  Rosanna Forteza; Susana M Casalino-Matsuda; Maria Elena Monzon; Erik Fries; Marilyn S Rugg; Caroline M Milner; Anthony J Day
Journal:  Am J Respir Cell Mol Biol       Date:  2006-07-27       Impact factor: 6.914

3.  Use of proteomics for validation of the isolation process of clotting factor IX from human plasma.

Authors:  James Clifton; Feilei Huang; Dajana Gaso-Sokac; Kate Brilliant; Douglas Hixson; Djuro Josic
Journal:  J Proteomics       Date:  2009-10-09       Impact factor: 4.044

4.  Glycosylation pattern of human inter-alpha-inhibitor heavy chains.

Authors:  C Flahaut; C Capon; M Balduyck; G Ricart; P Sautiere; J Mizon
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.